Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18908681 | 0.98 | MEN1 (0.48) | MAPK1KDM4EHIF1AMEN1KMT2A | |
| SCHEMBL22906372 | 0.98 | MEN1 (0.48) | MAPK1KDM4EHIF1AMEN1KMT2A | |
| SCHEMBL22526372 | 0.98 | MEN1 (0.48) | MAPK1KDM4EHIF1AMEN1KMT2A | |
| SCHEMBL22856478 | 0.98 | MEN1 (0.48) | MAPK1KDM4EHIF1AMEN1KMT2A | |
| SCHEMBL22856156 | 0.92 | MEN1 (0.44) | MAPK1KDM4EHIF1AMEN1KMT2A | |
| SCHEMBL5157716 | 0.91 | MAPK1 (0.55) | MAPK1KDM4EHIF1AMEN1KMT2A | |
| SCHEMBL5155263 | 0.88 | MEN1 (0.56) | MAPK1KDM4EHIF1AMEN1KMT2A | |
| SCHEMBL19309079 | 0.88 | MEN1 (0.56) | MAPK1KDM4EHIF1AMEN1KMT2A | |
| SCHEMBL24572134 | 0.88 | PAOX (0.41) | MAPK1KDM4EHIF1AMEN1KMT2A | |
| SCHEMBL12037859 | 0.88 | MAPK1 (0.50) | MAPK1KDM4EHIF1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024071371-A1 | HETEROCYCLIC COMPOUND | ユビエンス株式会社 | 2024-04-04 | — | — | WO | disclosed |
| EP-4268856-A1 | MULTILAYER STRUCTURE USING CHEMICALLY CROSSLINKED ALGINIC ACID | Mochida Pharmaceutical Co., Ltd. (JP) | 2023-11-01 | — | — | EP | disclosed |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| WO-2023114460-A1 | BCL6 DEGRADERS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2022145420-A1 | NOVEL MULTILAYER POLYMER-COATED CROSSLINKED ALGINATE GEL FIBER | 持田製薬株式会社 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022056273-A1 | LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022006007-A1 | METHODS FOR IMAGING BACTERIAL INFECTIONS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-01-06 | — | — | WO | disclosed |
| WO-2021195401-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | BIOHAVEN THERAPEUTICS LTD. (US) | 2021-09-30 | — | — | WO | disclosed |
| WO-2021104120-A1 | POLYETHYLENE GLYCOL CONJUGATE MEDICAMENT, PREPARATION METHOD THERFOR AND USE THEREOF | 重庆阿普格雷生物科技有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2020132588-A1 | COMBINATION THERAPY OF ARMS AND NATURAL KILLER CELLS | KLEO PHARMACEUTICALS, INC. (US) | 2020-06-25 | — | — | WO | disclosed |
| WO-2019023501-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-20120082728-A1 | MULTIFUNCTIONAL STEALTH NANOPARTICULES FOR BIOMEDICAL USE | UNIVERSITE DE STRASBOURG (FR) | 2012-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295180-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | MAPK1 3746/4885KDM4E 935/4885HIF1A 1784/4885 |
| US-20120082728-A1 | MULTIFUNCTIONAL STEALTH NANOPARTICULES FOR BIOMEDICAL USE | EPHA2, CD47, MSN | MAPK1 4213/4885KDM4E 3309/4885HIF1A 32/4885 |
| US-20230330240-A1 | TECHNOLOGIES FOR PREVENTING OR TREATING INFECTIONS | HAVCR2, ACE2, EPCAM | MAPK1 4307/4885KDM4E 2609/4885HIF1A 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.